Karyopharm Therapeutics Inc.
KPTI Healthcare Biotechnology
Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 11.9%, EPS grew 46.3%, free cash flow fell 33.3% and total debt rose 36.6%, each against the same quarter a year earlier.
Follow KPTI
Karyopharm Therapeutics Inc. (KPTI) EV/Sales
As of 16 October 2026, Karyopharm Therapeutics Inc. (KPTI) trades at a EV/Sales of 1.3×. Over the past ten years it has ranged from 0.3× (March 2019) to 4,298× (April 2015); the current reading is higher than 22% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.7× | 50.42% |
| FY2024 | 1.1× | 90.57% |
| FY2023 | 0.6× | (43.22%) |
| FY2022 | 1.0× | (48.86%) |
| FY2021 | 2.0× | (77.98%) |
| FY2020 | 9.1× | (64.09%) |
| FY2019 | 25.4× | 150.71% |
| FY2018 | 10.1× | (94.59%) |
| FY2017 | 187× | (85.60%) |
| FY2016 | 1,298× | 16.42% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.2× | 88.12% |
| Mar 2026 | 1.7× | 1.62% |
| Dec 2025 | 1.7× | 18.69% |
| Sep 2025 | 1.4× | 14.53% |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| APRE Aprea Therapeutics, Inc. compare | −35.7× |
| SNGX Soligenix Inc. compare | −3.7× |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| SNTI Senti Biosciences, Inc. compare | 0.3× |
| XTLB XTL Biopharmaceuticals Ltd. compare | 1.3× |
| KPTI Karyopharm Therapeutics Inc. | 1.3× |
| BOLT Bolt Biotherapeutics, Inc. compare | 1.6× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)